Table 2. Results for various cohort subsets.
| Cohort Subset Size & Description | Characteristic | Value |
|---|---|---|
| 792 subjects with completed TST and QFT-GIT | QFT-GIT Positive | 14 (1.8%) |
| TST > = 15 | 23 (2.9%) | |
| TST > = 10 | 42 (5.3%) | |
| TST Positive by Risk Stratified Interpretation | 38 (4.8%) | |
| QFT-GIT Indeterminate | 5 (0.6%) | |
| 787 subjects with completed TST and determinate QFT-GIT | Low risk of M. tuberculosis infection | 510 (64.8%) |
| Increased risk of M. tuberculosis infection | 277 (35.2%) | |
| 277 subjects at increased risk with completed TST and determinate QFT-GIT | QFT-GIT Positive | 8 (2.9%) |
| TST > = 15 | 18 (6.5%) | |
| TST > = 10 | 33 (11.9%) | |
| 510 subjects at low risk with completed TST and determinate QFT-GIT | QFT-GIT Positive | 6 (1.2%) |
| TST > = 15 | 5 (1.0%) | |
| TST > = 10 | 9 (1.8%) | |
| QFT-GIT Negative | 504 (98.8%) | |
| TST < 15 | 505 (99.0%) | |
| TST < 10 | 501 (98.2%) | |
| 807 subjects who had QFT-GIT and QFT-G completed | QFT-GIT positive | 14 (1.7%) |
| QFT-G positive | 5 (0.6%) | |
| QFT-GIT indeterminate | 5 (0.6%) | |
| QFT-G indeterminate | 16 (2.0%) | |
| 787 subjects with determinate QFT-GIT and QFT-G | QFT-GIT positive | 11 (1.4%) |
| QFT-G positive | 5 (0.6%) | |
| 769 subjects with competed TST and determinate QFT-GIT and QFT-G results | Low risk | 500 (65.0%) |
| 500 subjects at low risk with determinate QFT-G, QFT-GIT, and TST results | QFT-GIT negative | 497 (99.4%) |
| QFT-G negative | 499 (99.8%) | |
| TST <15 | 495 (99.0%) | |
| TST <10 | 491 (98.2%) |
TST = tuberculin skin test; QFT-GIT = QuantiFERON®-TB Gold In-Tube test; QFT-G = QuantiFERON®-TB Gold test.